These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1389 related articles for article (PubMed ID: 24439393)

  • 1. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B
    Transplant Proc; 2013; 45(1):407-14. PubMed ID: 23375330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
    Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
    Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis in hematopoietic stem cell transplant recipients.
    Marr KA
    Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):15-9. PubMed ID: 11757846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
    BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
    Strasfeld L; Weinstock DM
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.